Avid Bioservices Inc (CDMO)

[bigbro1]

Take away ! Thanks

Of course as discussed in Bio’s and CP posts, the main points are that (1) Opdivo won’t be approved in the U.S for non-squamous NSCLC in time to affect enrollment at the US sites, (2) Opdivo will not be available at any of the non-US sites, and (3) the largest factor impacting enrollment will be the total number of other trials also recruiting similar NSCLC patients, and now that the BMY trial is finished Bavi has one less competitor to deal with.